LOGO
LOGO

Slide Shows

Tracking Coronavirus Vaccines In Human Trials

#17 CVnCoV
#17 CVnCoV

CVnCoV vaccine is being developed by CureVac AG

Current status: The vaccine is under a phase I trial in Belgium and Germany.

Mode of Action: CVnCoV contains mRNA that encodes the full-length spike protein of SARS-CoV-2 and is formulated with lipid nanoparticles (LNP).

Next Milestone:

The phase I trial is expected to be completed by August 2021.